Brief: Novartis Rhapsido wins EC approval as first oral targeted CSU treatment
27/04/2026 06:17
April 27 (Reuters) - Novartis AG NOVN.S: NOVARTIS RHAPSIDO® RECEIVES EUROPEAN COMMISSION APPROVAL AS FIRST ORAL TARGETED TREATMENT FOR CHRONIC SPONTANEOUS URTICARIA Source text: ID:nGNE3vjHH3 Further company coverage: NOVN.S (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Novartis AG
See all newsBrief: Novartis Remind Data At Eaaci Show Rhapsido Potential As First Targeted Therapy For Chronic Inducible Urticaria (Cindu)
Swiss stocks - Factors to watch on June 12
Swiss pharma hub Basel frets over population cap threat
Novartis says rare muscle disease drug shows promise in early trial
Live Markets: Europe at half-time: countdown to the ECB's 'insurance hike'